GO:0120022 glucagon family peptide binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0120022 (glucagon family peptide binding) is a molecular function defined as binding to a member of the glucagon family peptide hormone, including glucagon, glucagon-like peptides, oxyntomodulin, glicentin, ADCYAP1, GHRH, secretin, VIP, and GIP.
• This binding activity is central to incretin biology, where GIP and GLP-1 bind their cognate receptors to potentiate glucose-dependent insulin secretion.
• The glucagon receptor (GCGR) is a class B G protein-coupled receptor that binds glucagon and mediates its metabolic effects.
• Dysregulation of glucagon family peptide binding contributes to metabolic disorders such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease.
• Experimental models for studying this function include receptor knockout, point-mutation, and knock-in cell lines, as well as CRISPR library screening.
• Understanding glucagon family peptide binding informs therapeutic development, including dual and triple agonists for metabolic disease.
Description
Glucagon family peptide binding (GO:0120022) is a molecular function that describes the selective interaction of a protein with any member of the glucagon peptide hormone family. This family includes glucagon, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), oxyntomodulin, glicentin, pituitary adenylate cyclase-activating polypeptide (ADCYAP1), growth hormone-releasing hormone (GHRH), secretin, vasoactive intestinal peptide (VIP), and glucose-dependent insulinotropic polypeptide (GIP). These peptides are structurally related and exert diverse physiological roles, from glucose homeostasis to gut motility and neuroendocrine regulation. The binding event is the first step in receptor activation and signal transduction, making it a critical node for both basic research and drug discovery. Researchers study this function to understand how metabolic hormones control energy balance, insulin secretion, and organ cross-talk. The glucagon receptor (GCGR) and the incretin receptors (GIPR and GLP-1R) are the best-characterized binding partners, and their interactions are implicated in type 2 diabetes, obesity, and fatty liver disease. Because of its clinical relevance, GO:0120022 is a frequent target in CRISPR-based functional genomics, where knockout and knock-in models help dissect ligand-receptor specificity and downstream signaling.
glucagon family peptide binding At A Glance
| GO ID | GO:0120022 |
|---|---|
| GO term | glucagon family peptide binding |
| Ontology | molecular_function |
| Synonym | glucagon binding, glucagon-like peptide binding |
| Major function | Binding to glucagon family peptide hormones such as glucagon, GLP-1, GIP, secretin, VIP, and related peptides |
| Representative ligands | Glucagon, GLP-1, GLP-2, oxyntomodulin, glicentin, ADCYAP1, GHRH, secretin, VIP, GIP |
| Representative receptors | GCGR, GLP-1R, GLP-2R, GIPR, SCTR, VIPR1, VIPR2, PAC1, GHRHR |
| Associated diseases | Type 2 diabetes, obesity, non-alcoholic fatty liver disease, metabolic syndrome |
| Research methods | CRISPR knockout/knock-in, binding assays, cAMP assays, multi-omics, structural biology |
What Is GO:0120022?
In simple terms, GO:0120022 describes the ability of a protein to physically bind to a glucagon family peptide hormone. The QuickGO definition states: Binding to a member of the glucagon family peptide hormone (e.g. glucagon, glucagon-like peptides, oxyntomodulin, glicentin, ADCYAP1, GHRH, secretin, VIP, GIP). This function is typically mediated by class B G protein-coupled receptors, such as the glucagon receptor, GLP-1 receptor, GIP receptor, secretin receptor, and VIP receptors, which recognize the peptide ligand with high specificity. The binding event triggers conformational changes that activate intracellular signaling cascades, including cAMP production and protein kinase A activation. Synonyms for this term include glucagon binding and glucagon-like peptide binding.
Why Is glucagon family peptide binding Important in Cell Biology?
GO:0120022 is important because glucagon family peptides are master regulators of metabolism, and their binding to receptors controls insulin secretion, glucose production, satiety, and energy expenditure. Dysregulation of these interactions is a hallmark of type 2 diabetes, obesity, and non-alcoholic fatty liver disease, making them prime therapeutic targets. Moreover, the binding specificity of these peptides determines the efficacy and side effects of incretin-based drugs, such as GLP-1 receptor agonists and dual agonists. Understanding the molecular details of ligand-receptor binding is therefore essential for rational drug design and for interpreting genetic variants that alter receptor function.
• Glucagon family peptide binding initiates signaling that controls blood glucose and insulin secretion.
• It is the molecular basis for incretin hormone action, which is exploited in diabetes therapies.
• Dysregulated binding contributes to insulin resistance and hyperglycemia in type 2 diabetes.
• It plays a role in lipid metabolism and the pathogenesis of non-alcoholic fatty liver disease.
• It is involved in satiety signaling and energy homeostasis, relevant to obesity.
• Binding specificity determines the pharmacological profile of peptide-based drugs.
• Genetic variants in receptors can alter binding affinity and disease risk.
• CRISPR screens targeting these interactions can identify novel regulators of metabolic signaling.
• It is a model system for studying class B GPCR activation and biased agonism.
• It links gut hormone biology to systemic metabolic control, offering multi-organ therapeutic opportunities.
Molecular Mechanism of glucagon family peptide binding
Ligand recognition and binding pocket
In simple terms: The receptor has a pocket that fits the peptide hormone like a lock and key.
Glucagon family peptides bind to the extracellular domain of class B GPCRs, primarily through interactions with the N-terminal ectodomain and the transmembrane helix bundle. For the glucagon receptor, the peptide's C-terminal region binds the receptor's N-terminal domain, while the N-terminal region inserts into the transmembrane core to trigger activation. This two-step mechanism ensures high specificity and allows discrimination among closely related peptides such as glucagon and GLP-1.
Receptor conformational change and G protein coupling
In simple terms: Once the hormone binds, the receptor changes shape and activates a G protein inside the cell.
Ligand binding induces conformational rearrangements in the receptor's transmembrane helices, leading to the formation of a cavity that engages the Gs protein. This interaction promotes GDP-GTP exchange on the Gαs subunit, which then activates adenylyl cyclase to produce cAMP. cAMP serves as a second messenger that activates protein kinase A (PKA) and other effectors, propagating the signal.
Signal amplification and downstream effects
In simple terms: The initial binding event is amplified into a large cellular response.
The cAMP/PKA pathway phosphorylates multiple targets, including ion channels and transcription factors, to regulate insulin secretion, gluconeogenesis, and lipid metabolism. In pancreatic beta cells, GLP-1 and GIP binding enhances glucose-stimulated insulin secretion through cAMP-dependent and independent mechanisms. In hepatocytes, glucagon binding stimulates glycogenolysis and gluconeogenesis via PKA and CREB.
Desensitization and regulation of binding
In simple terms: Cells can turn down the response after prolonged stimulation.
Following sustained agonist exposure, glucagon family receptors undergo phosphorylation by G protein-coupled receptor kinases (GRKs) and recruit β-arrestins, leading to desensitization and internalization. This negative feedback prevents overstimulation and is critical for maintaining metabolic homeostasis. Dysregulation of this process can contribute to hormone resistance in metabolic diseases.
Structural determinants of peptide specificity
In simple terms: Small differences in the hormone sequence determine which receptor it binds.
The glucagon family peptides share a conserved N-terminal region but diverge in their C-terminal sequences, which dictate receptor selectivity. For example, GLP-1 and GIP bind distinct receptors despite both being incretins, due to differences in their receptor-binding epitopes. Structural studies of GCGR and GLP-1R have revealed key residues that mediate ligand discrimination, providing templates for designing biased agonists.
Key Genes Involved in GO:0120022 glucagon family peptide binding
The following genes encode receptors and ligands that mediate or regulate glucagon family peptide binding, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GCGR | Binds glucagon to regulate glucose homeostasis | Target for type 2 diabetes and obesity; knockout models show altered glycemia |
| GLP1R | Binds GLP-1 to potentiate insulin secretion | Therapeutic target for diabetes and obesity; CRISPR knockouts validate signaling |
| GIPR | Binds GIP to enhance insulin secretion | Incretin receptor; dual agonists target GIPR and GLP1R |
| GLP2R | Binds GLP-2 to regulate intestinal growth | Relevant to short bowel syndrome and intestinal repair |
| SCTR | Binds secretin to regulate pancreatic bicarbonate secretion | Model for class B GPCR activation |
| VIPR1 | Binds VIP to modulate smooth muscle and immune function | Implicated in neuroendocrine and inflammatory pathways |
| VIPR2 | Binds VIP and PACAP to regulate circadian and neuronal signaling | Associated with psychiatric and metabolic phenotypes |
| ADCYAP1R1 | Binds PACAP to regulate stress responses | Target for migraine and neuroprotection research |
| GHRHR | Binds GHRH to control growth hormone release | Mutations cause dwarfism; model for receptor binding |
| GCG | Encodes glucagon and related peptides | Precursor for glucagon, GLP-1, GLP-2, oxyntomodulin |
| GIP | Encodes glucose-dependent insulinotropic polypeptide | Incretin hormone; knockout models show impaired insulin secretion |
| GLP1 | Encodes GLP-1 peptide | Key incretin; basis for GLP-1 receptor agonist drugs |
| GLP2 | Encodes GLP-2 peptide | Regulates intestinal epithelial growth |
| ADCYAP1 | Encodes PACAP peptide | Binds PAC1 receptor; involved in stress and metabolism |
| GHRH | Encodes growth hormone-releasing hormone | Binds GHRHR; regulates growth |
| SCT | Encodes secretin peptide | Binds secretin receptor; regulates digestion |
| VIP | Encodes vasoactive intestinal peptide | Binds VIP receptors; neuromodulator |
How Is glucagon family peptide binding Regulated?
The binding of glucagon family peptides to their receptors is regulated at multiple levels. Ligand availability is controlled by secretion from enteroendocrine cells and pancreatic alpha cells, which is influenced by nutrient intake. Receptor expression levels can be modulated by metabolic status, such as in high-fat diet-induced obesity, where changes in receptor density affect hormone sensitivity. Post-translational modifications, including phosphorylation and glycosylation, can alter binding affinity. Additionally, desensitization mechanisms involving GRK-mediated phosphorylation and β-arrestin recruitment provide negative feedback. In disease states like non-alcoholic fatty liver disease, autophagy dysfunction may impact receptor turnover and signaling.
glucagon family peptide binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GCGR | Type 2 diabetes, hyperglycemia | Knockout cell line, point-mutation knock-in for ligand binding residues |
| GLP1R | Type 2 diabetes, obesity | Overexpression and CRISPR knockout in pancreatic beta cells |
| GIPR | Incretin dysfunction, obesity | Dual agonist studies, receptor knock-in models |
| GHRHR | Growth hormone deficiency | Point-mutation knock-in to mimic patient variants |
| VIPR2 | Circadian rhythm and psychiatric disorders | Knockout and tagged knock-in for imaging |
Type 2 diabetes and incretin dysfunction
In type 2 diabetes, impaired binding of GLP-1 and GIP to their receptors contributes to reduced insulin secretion and hyperglycemia. Genetic variants in GLP1R and GIPR have been associated with altered glucose tolerance. Therapies that enhance incretin receptor binding, such as GLP-1 receptor agonists, are mainstays of diabetes treatment.
Obesity and metabolic syndrome
Glucagon family peptides regulate satiety and energy expenditure, and their binding to hypothalamic receptors influences food intake. Dysregulated GLP-1 signaling is linked to obesity, and dual agonists targeting GLP-1R and GIPR show enhanced weight loss in clinical trials. CRISPR models of receptor knockout help dissect these effects.
Non-alcoholic fatty liver disease (NAFLD)
Glucagon signaling in the liver promotes gluconeogenesis and lipid oxidation, and its dysregulation is implicated in NAFLD. High-fat diet-induced NAFLD models show altered autophagy and glucagon receptor signaling. Targeting glucagon family peptide binding may offer therapeutic strategies for fatty liver disease.
Neuroendocrine and growth disorders
Mutations in GHRHR that impair GHRH binding cause isolated growth hormone deficiency. Similarly, defects in VIP and PACAP binding are associated with neurological and circadian disorders. These rare monogenic disorders highlight the importance of precise ligand-receptor interactions.
From glucagon family peptide binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GCGR affect glucose homeostasis? | GCGR knockout cell line or animal model |
| How do point mutations in GLP1R alter ligand binding? | Point-mutation knock-in via CRISPR |
| Can tagged receptors track binding dynamics? | Tagged knock-in (e.g., GFP or HA) of GLP1R |
| What is the effect of receptor overexpression on signaling? | Overexpression cell model with inducible promoter |
| Which genes regulate glucagon family peptide binding? | CRISPR library screening in relevant cell types |
| How does GIPR signaling contribute to obesity? | Knock-in of humanized GIPR in mouse models |
How to Study the glucagon family peptide binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Ligand-receptor affinity and kinetics | Characterizing GCGR and GLP-1R binding |
| cAMP assay | G protein activation | Screening agonists/antagonists |
| CRISPR knockout screen | Gene essentiality for binding | Identifying novel regulators |
| RNA-seq | Transcriptional changes | Pathway analysis after receptor modulation |
| Proteomics | Protein expression and interactions | Mapping signaling complexes |
| Live-cell imaging | Receptor internalization and trafficking | Studying desensitization |
| Structural biology (cryo-EM) | 3D structure of ligand-receptor complexes | Rational drug design |
Binding assays (radioligand and fluorescence)
Direct binding assays using radiolabeled or fluorescently labeled glucagon family peptides measure affinity and kinetics. These assays are used to determine Kd and Bmax for receptors such as GCGR and GLP-1R.
cAMP and downstream signaling assays
Functional assays measuring cAMP accumulation or PKA activity quantify receptor activation upon ligand binding. These are standard for characterizing agonist and antagonist potency.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate glucagon family peptide binding and signaling. Such screens have uncovered modifiers of incretin receptor function.
Multi-omics and bioinformatics
Transcriptomics, proteomics, and metabolomics can reveal global changes in gene expression and metabolite profiles associated with altered binding. Bioinformatics integration identifies pathways and biomarkers.
How CRISPR Can Be Used to Study GO:0120022 glucagon family peptide binding
Knockout
CRISPR knockout of receptors such as GCGR or GLP1R eliminates binding and downstream signaling, providing a clean background to study ligand specificity. Knockout cell lines are used to validate drug targets and to assess compensatory mechanisms.
Point Mutation
Point mutations introduced by CRISPR base editing or HDR can mimic naturally occurring variants that alter binding affinity. These models help determine the structural basis of ligand recognition and disease-associated mutations.
Knock-in
Knock-in of tagged or humanized receptors allows tracking of binding dynamics and species-specific pharmacology. For example, inserting a fluorescent tag into GLP1R enables live-cell imaging of ligand-induced internalization.
Overexpression
Overexpression of glucagon family receptors or ligands via CRISPR activation or cDNA integration amplifies signaling and can reveal saturating effects. This approach is useful for studying downstream pathways and for drug screening.
How EDITGENE Supports glucagon family peptide binding Research
Researchers studying glucagon family peptide binding-related genes often need to determine whether a candidate gene is causally involved in ligand recognition, receptor activation, or downstream metabolic effects. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for glucagon family peptide binding research.
Frequently Asked Questions About glucagon family peptide binding
What is GO:0120022?
GO:0120022 is the Gene Ontology molecular function term for glucagon family peptide binding, defined as binding to a member of the glucagon family peptide hormone.
What genes are involved in glucagon family peptide binding?
Key genes include GCGR, GLP1R, GIPR, GLP2R, SCTR, VIPR1, VIPR2, ADCYAP1R1, and GHRHR, which encode receptors for glucagon, GLP-1, GIP, and related peptides.
What diseases are associated with glucagon family peptide binding?
Dysregulation is linked to type 2 diabetes, obesity, non-alcoholic fatty liver disease, and rare growth disorders.
How is glucagon family peptide binding studied?
Common methods include radioligand binding assays, cAMP assays, CRISPR knockout screens, and structural biology.
What are the synonyms for GO:0120022?
Synonyms include glucagon binding and glucagon-like peptide binding.
Which receptors bind glucagon family peptides?
Class B GPCRs such as GCGR, GLP-1R, GIPR, secretin receptor, VIP receptors, PAC1, and GHRHR bind these peptides.
Why is glucagon family peptide binding important for drug discovery?
It is the target of incretin-based therapies for diabetes and obesity, and understanding binding informs agonist design.
Can CRISPR be used to study glucagon family peptide binding?
Yes, CRISPR knockout, knock-in, and point mutations are widely used to dissect receptor-ligand interactions.
What is the role of GLP-1 binding in insulin secretion?
GLP-1 binding to its receptor enhances glucose-dependent insulin secretion via cAMP signaling.
How does glucagon receptor binding affect liver metabolism?
Glucagon binding stimulates glycogenolysis and gluconeogenesis in the liver, regulating blood glucose.
Conclusion
GO:0120022 (glucagon family peptide binding) is a fundamental molecular function that underlies the action of incretin and other metabolic hormones. Its dysregulation is central to type 2 diabetes, obesity, and fatty liver disease, making it a high-priority target for therapeutic development. Advances in CRISPR-based models and multi-omics approaches continue to unravel the precise mechanisms of ligand-receptor recognition and signaling. EDITGENE offers end-to-end services to support researchers in this field, from knockout cell lines to CRISPR library screening.
References
- 1. Ren Q et al.. 2024. Dysfunction of autophagy in high-fat diet-induced non-alcoholic fatty liver disease.. Autophagy 20(2):221-241 PMID: 37700498
- 2. Seino Y et al.. 2010. GIP and GLP-1, the two incretin hormones: Similarities and differences.. J Diabetes Investig 1(1-2):8-23 PMID: 24843404
- 3. Wang D et al.. 2021. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease.. Nat Rev Endocrinol 17(10):592-607 PMID: 34381196
- 5. Fang X et al.. 2022. Advances in multi-omics study of biomarkers of glycolipid metabolism disorder.. Comput Struct Biotechnol J 20:5935-5951 PMID: 36382190
- 7. Authier F et al.. 2008. Glucagon receptors.. Cell Mol Life Sci 65(12):1880-99 PMID: 18292967
- 8. Fletcher MM et al.. 2021. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.. J Pharmacol Exp Ther 377(3):417-440 PMID: 33727283
